Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1469-8749.1993.tb11588.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hemato-Renal Profile of Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits.
Indian J Nephrol
July 2024
Departments of Nephrology, Christian Medical College Vellore, Ranipet Campus, Ranipet, India.
Background: Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is a rare entity classified under the umbrella of monoclonal gammopathy of renal significance. The clinical implications of circulating monoclonal immunoglobulin (MIg), light chain restriction on immunofluorescence (IF) microscopy, histopathological pattern, and type of therapy on renal outcomes are not clearly defined.
Materials And Methods: Sixteen patients of PGNMID diagnosed between 2013 and 2020 were included from a biopsy registry of 11,459 patients at a single center.
Gender equality and quality of life must be central to the design and delivery of sanitation.
BMJ Glob Health
January 2025
Department of Disease Control, London School of Hygiene and Tropical Medicine, London, UK.
Quality of Life and Social Health in Patients After Pancreatic Surgery.
J Gastrointest Surg
January 2025
Department of Surgery, University of Arizona, Tucson, AZ. Electronic address:
Background: Clinicians lack robust data on quality of life and social functioning after pancreatectomy limiting their ability guide patient decision-making aligned with patients' goals of care.
Methods: In this cross-sectional survey study, we administered the European Organization for Research and Treatment of Cancer Core Quality of Life questionnaire (EORTC QLQ-C30); pancreas-specific QLQ-PAN26; Patient-Reported Outcomes Measurement Information System (PROMIS™) Ability to Participate in Social Roles; and PROMIS™ Activities and social Isolation scales to all elective pancreatectomies (2021-2023). Results were compared to both normative data and between groups to determine factors predicting better QOL with a >10-12-point change considered clinically significant.
Functional movement disorders in dopa-responsive dystonia.
Parkinsonism Relat Disord
January 2025
Institute of Systems Motor Science, University Medical Center Schleswig-Holstein, University of Lübeck, Lübeck, Germany; Center for Brain, Behavior, and Metabolism, University of Lübeck, Lübeck, Germany; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, United States; Center of Rare Diseases, University Medical Center Schleswig-Holstein, Lübeck, Germany. Electronic address:
Background: Functional neurological movement disorders are common and disabling. Little is known about their coexistence with other non-functional movement disorders and their impact on the general disease burden.
Objectives: Investigating frequency and characteristics of functional movement disorders in GCH1-positive dopa-responsive dystonia patients.
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results.
Gynecol Oncol
January 2025
University of Siena and Center for Immuno-Oncology, Department of Oncology, University Hospital, Siena, Italy. Electronic address:
Objective: We report updated results with longer follow-up in patients with MSI-H/dMMR endometrial cancer (EC) in cohort D (advanced EC of any MSI/dMMR status) and cohort K (any MSI-H/dMMR advanced solid tumor, except colorectal) of the phase 2 KEYNOTE-158 study (NCT02628067) and the first results from patients with non-MSI-H/non-dMMR advanced EC (cohort D).
Methods: Patients received pembrolizumab 200 mg Q3W for ≥35 cycles. The primary endpoint was objective response rate (ORR) per RECIST v1.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!